CXCL10 and COVID-19: This is corroborated by conclusions from Kazer et al. and Wilk et al.; the former reported the enrichment of CXCL10+ inflammatory monocytes in HIV-1+ individuals, while the latter reported the enrichment of IFN-I-expressing inflammatory monocytes in COVID-19 patients.